Applications of Beclomethasone in Industrial Manufacturing

As an established manufacturer, we supply Beclomethasone for critical downstream processes in regulated industries. Below, we outline primary application scenarios in which our material integrates into industrial-scale pharmaceutical and specialty manufacturing, focusing on real-world usage, compliance, and end product types.

1. Inhaled Corticosteroid Formulation for Respiratory Aerosols

Beclomethasone is a primary active ingredient in large-scale pharmaceutical production of aerosolized corticosteroid solutions and suspensions for respiratory disease management. Pharmaceutical processors employ it in metered-dose inhalers during batch preparation, where precise dispersion minimizes particulate aggregation and ensures consistent patient dosing.

Industry compliance standards

• USP Monograph Beclomethasone Dipropionate
• European Pharmacopoeia (Ph. Eur.) 11.0
• ICH Q7 GMP for Active Pharmaceutical Ingredients
• 21 CFR Part 210/211 (US cGMP for finished pharmaceuticals)

Typical usage ratio

• 100–250 micrograms per inhaler dose; bulk batch concentrations typically range from 0.01%–0.025% w/w, adjusted based on required actuation dosage and inhaler fill volume.

Downstream process integration

• Added to pre-sterilized suspension medium or ethanol-based propellant mix during solution preparation before filling into aerosol canisters. Integration includes dispersion, micronization, and homogenization to control particle size, in QA-verified controlled areas.

Final product types

• Metered-dose inhalers (MDIs)
• Dry powder inhalers (DPIs)
• Nebulizer suspension ampules

2. Topical Glucocorticoid Creams and Ointments

Beclomethasone is utilized in the fabrication of dermal pharmaceutical preparations for inflammatory skin disorders. Manufacturers incorporate it during the controlled mixing and emulsification of oil, water, and active phases, where material dissolution, compatibility with excipients, and preservative stability are critical for final product homogeneity.

Industry compliance standards

• British Pharmacopoeia (BP) monographs for topical corticosteroids
• ICH Q8 (Pharmaceutical Development)
• ISO 22716 (Cosmetic GMP, where used in non-prescription topical products)
• EMA Quality of Medicines Documents (CMDh guideline)

Typical usage ratio

• 0.025%–0.1% w/w within finished creams or ointments, specified according to regulatory monographs and disease indication. Lower ranges apply for pediatric or sensitive skin formulations.

Downstream process integration

• Material is solubilized and added post-melting of wax and pre-cooling in high-shear mixer, ensuring uniform distribution. Final mixing precedes automated filling into primary packaging under validated conditions with in-line QC for content uniformity.

Final product types

• Dermatological creams
• Emollient ointments
• Topical gels
• Medicated liquid lotions

3. Intranasal Steroid Spray Manufacturing

Leading pharmaceutical firms use Beclomethasone in the compounding of intranasal sprays for allergy and rhinitis control. Processors require micronized API addition into sterile suspension media, emphasizing filtration and anti-microbial preservative compatibility to comply with multi-dose packaging standards and prevent crystal growth during shelf-life.

Industry compliance standards

• United States Pharmacopeia (USP) intranasal preparation requirements
• EU GMP Volume 4 (Annex 1: Manufacture of Sterile Products)
• ICH Q6A (Specifications: Test Procedures and Acceptance Criteria)
• Pharmacopoeia of the People’s Republic of China (Volume IV, where applicable)

Typical usage ratio

• 0.05% w/v within final nasal spray solutions, generally 50 micrograms per actuation, titrated to clinical specification and global monograph limits.

Downstream process integration

• API is micronized and dispersed directly into cooled aqueous buffer systems, then homogenized in closed jacketed tanks. Post-mixing, solution undergoes sterile filtration, preservative optimization, and gravity-fed filling into nasal spray bottles under cleanroom conditions.

Final product types

• Metered nasal spray (aqueous and suspension forms)
• Nasal drops (for international markets)

4. Rectal and Enema Suspension Preparation

Specialized factories utilize Beclomethasone for the production of corticosteroid rectal foams, enemas, and suppositories targeting ulcerative colitis and proctitis. Here, the formulation requires precise dispersion of the API in semi-solid and liquid media, with rigorous validation of dose delivery and mucosal compatibility throughout commercial batch runs.

Industry compliance standards

• Ph. Eur. 2.9.40 (Uniformity of dosage units)
• WHO GMP for sterile/special products
• FDA Guidance for Industry: Suppositories & Rectal Dosage Forms
• Japanese Pharmacopeia, Rectal Preparations Monograph

Typical usage ratio

• Approximately 3 mg–5 mg per unit for rectal foam and enema preparations; bulk product blended to deliver per-dose requirement, with total API concentration typically between 0.05%–0.1% w/w in the base medium.

Downstream process integration

• Incorporated in the liquid or semi-solid phase under vacuum mixing before emulsification. Steps include heat-optional dispersion in aqueous or propellant vehicle, QA-verified batch sampling, and aseptic filling/sealing of final units.

Final product types

• Rectal foam aerosols
• Enema suspensions
• Suppositories